Who should pay for failed devices?; Dexcom snags FDA nod for next-gen glucose monitor;

 @FierceMedDev: U.S. regulators are worried about an off-label use of stents or balloons to treat MS. More | Follow @FierceMedDev

 @MarkHFierce: CareFusion acquires a Brazilian respiratory company. More | Follow @MarkHFierce

 @DamianFierce: Olympus Biotech is tossing its hat into the CMO ring. More | Follow @DamianFierce

> Insurers are trying to recover more of the healthcare-related costs associated with medical device failures from the device companies themselves. Story

> St. Jude Medical ($STJ) unveiled new technology designed to help evaluate vascular and cardiac conditions on a recorded fluoroscopic image instead of live fluoroscopy, with a goal of reducing radiation exposure. Release

> The FDA has signed off on Dexcom's ($DXCM) new continuous glucose monitoring system, which is designed to be much more accurate in determining when patients are hypoglycemic. Release

> Boston Scientific ($BSX) will release its 2012 third-quarter results Oct. 18. Release

> Xconomy's Luke Timmerman says San Francisco is the clear No. 1 biotech hub, but Boston is hot on its heels. Article

> Researchers from Austria and Germany believe a nanotechnology material, made, in part, from licorice could help better sterilize medical devices and implants. Release

Biotech News

 @FierceBiotech: ACRO decries TV portrayal of clinical. More | Follow @FierceBiotech

 @JohnCFierce: Honey, we shrunk the biotech: Targacept cuts back (again). Release | Follow @JohnCFierce

 @RyanMFierce: Life Technologies bought a bioinformatics group, Compendia, a U of Mich. spinoff. Terms undisclosed. More | Follow @RyanMFierce

> Stem cell pioneers win this year's Nobel prize for medicine. Story

> AstraZeneca bags PhIIb-ready CKD drug in $272M Ardelyx partnership. Article

> Troubled Targacept whacks laboratory ops in latest restructuring. News

Pharma News

@FiercePharma: A head-scratcher for SEC: Pfizer reports U.S. loss, $15B in overseas profits. More | Follow @FiercePharma

> Novartis CEO: No on megadeals, yes on dividend. Story

> Novo exec welcomes the Bristol-AZ diabetes blitz. Article

CRO News

> Quintiles looks to Scotland for clinical trial growth. Article

> Icon partners with Korean CRO group. More

> Catalent, Parexel team up for trial supply. News

> Olympus Biotech jumps into CMO game. Story

Biotech IT News

> Oracle, IBM support $100M personalized medicine effort at UPMC. Article

> Biotech billionaire's supercomputer cuts cancer analysis to 47 seconds. Story

> 'Big Data' startup wins deal with Aptalis Pharma. More

Suggested Articles

The ADDF announced its second round of research awards, with a total of $6 million in new funding for diagnostic tests.

Takeda teamed up with Enzyre to develop an at-home diagnostic device that will help people with hemophilia determine their own coagulation status.

Foundation Medicine received a diagnostic approval from the FDA for selecting HR+/HER2- breast cancer patients for treatment with Novartis' Piqray.